United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) of Piramal Pharma’s PPDS Ahmedabad facility from July 10, 2024 to July 12, 2024. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.
Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to the company's high-end analytical capabilities to its customers for their clinical and commercial batches from an FDA approved site. The company remains committed to maintain the highest standards of compliance.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1747.25 |
Dr. Reddys Lab | 1174.85 |
Cipla | 1528.10 |
Lupin | 2046.90 |
Zydus Lifesciences | 852.50 |
View more.. |